Screener
Xeris Biopharma Holdings, Inc. XERS Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Interest expense | (6,947) | (7,358) | (13,831) | (14,663) |
| Total other expense | (36,274) | (6,410) | (41,956) | (12,540) |
| Net loss before income taxes | (31,101) | (1,928) | (28,867) | (11,148) |
| Income tax benefit | — | — | — | — |
| Net loss | $(31,101) | $(1,928) | $(28,867) | $(11,148) |
| Other comprehensive income (loss), net of tax: | ||||
| Foreign currency translation adjustments | 14 | 1 | 15 | 1 |
| Comprehensive loss | $(31,087) | $(1,927) | $(28,852) | $(11,147) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s income tax?
- Xeris Biopharma Holdings, Inc. (XERS) reported income tax of $0 in Q2 2026.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Xeris Biopharma Holdings, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude